articleTop 1% cited
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Journal of Hepatology · 2013 · Vol. 59(1) · pp. 81–88
Bruno Sangro✉(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)Carlos Gómez-Martín(Hospital Universitario 12 De Octubre)Manuel de la Mata(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)Mercedes Iñarrairaegui(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)Elena Garralda(Hospital Universitario 12 De Octubre)Pilar Barrera(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)José Ignacio Riezu‐BojEsther LarreaCarlos Alfaro(Clinica Universidad de Navarra)Pablo SarobeJuan José LasarteJosé Luis Perez‐Gracia(Clinica Universidad de Navarra)Ignacio Melero(Clinica Universidad de Navarra)Jesús Prìeto(Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Hepatitis C virus researchCancer Immunotherapy and Biomarkersinterferon and immune responsesTremelimumabMedicineHepatocellular carcinomaInternal medicineImmunologyCirrhosisHepatitis CGastroenterologyAdverse effectHepatitis C virus
MeSH terms
AgedAntibodies, MonoclonalAntineoplastic AgentsAntiviral AgentsFemaleCarcinoma, HepatocellularHumansLiver CirrhosisLiver NeoplasmsMaleMiddle AgedPilot ProjectsHepacivirusViral LoadHepatitis C, Chronic
Funding
- Pfizer
- Instituto de Salud Carlos III
Citations
982
FWCI
18.97
field-weighted impact
References
39
Percentile
100%
vs. same field & year
Citations per year
Cited by
Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Cells · 2020 · 489 citations
T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance
Cell Death and Disease · 2015 · 377 citations
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
Annals of Oncology · 2015 · 885 citations
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review
Annals of Oncology · 2017 · 898 citations
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology · 2018 · 1,047 citations
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
The Lancet Oncology · 2018 · 2,498 citations
References
Sorafenib in Advanced Hepatocellular Carcinoma
New England Journal of Medicine · 2008 · 12,835 citations
Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Journal of Hepatology · 2001 · 4,075 citations
The blockade of immune checkpoints in cancer immunotherapy
Nature reviews. Cancer · 2012 · 13,550 citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
New England Journal of Medicine · 2010 · 15,037 citations
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
JNCI Journal of the National Cancer Institute · 2000 · 15,689 citations
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Journal of Hepatology · 2018 · 11,335 citations
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
Journal of Hepatology · 2012 · 5,186 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.